Literature DB >> 1653749

Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis.

J G McHutchison1, G Kuo, M Houghton, Q L Choo, A G Redeker.   

Abstract

Hepatitis C virus antibodies were measured in 213 patients who had acute (n = 122) and chronic (n = 91) non-A, non-B hepatitis. In acute infection, anti-hepatitis C virus was detected in 61% of IV drug abusers, in 33% of patients with transfusion-associated hepatitis, and in 22% of patients with sporadic infections (P less than 0.0005, drug abusers vs. sporadic). Mean time to seroconversion was 11.6 weeks (range, 1-80 weeks). Anti-hepatitis C virus was more common in chronic infection (P less than 0.001) and was more often detected in IV drug users (89%; P less than 0.0001) and after transfusion (71%; P less than 0.005) compared with chronic sporadic infection (27%). Antibody persisted for up to 8 years. Six chronic case patients (8.3%) later lost antibody (mean, 24 months; range, 12-48 months).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653749     DOI: 10.1016/0016-5085(91)90742-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

Review 1.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

2.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

3.  Acute non-A, non-B hepatitis in Italy: a 16-year prospective epidemiological study. The possible role of hepatitis C virus.

Authors:  F Bortolotti; C Crivellaro; M Carretta; A Tagger; M Ribero; A Bertolini; E Barbierato; F Noventa; P Cadrobbi
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

4.  Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus.

Authors:  E P Miskovsky; A V Carrella; K Gutekunst; C A Sun; T C Quinn; D L Thomas
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

5.  Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.

Authors:  P J Chen; J T Wang; L H Hwang; Y H Yang; C L Hsieh; J H Kao; J C Sheu; M Y Lai; T H Wang; D S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 6.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

7.  Epidemiological, clinical and biological characteristics of acute non-A, non-B hepatitis with and without hepatitis C virus infection.

Authors:  C A Navascués; M Rodríguez; N G Sotorrío; P Leiva; A Martínez; R Pérez; J de la Vega; L Rodrigo
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.